The sleep-wake circuit regulates arousal, alertness, and circadian rhythms through a network of wake-promoting and sleep-promoting neurons. Sleep disorders are among the most common non-motor symptoms in Parkinson's disease and Alzheimer's disease[1].
The reticular formation in the brainstem projects to the thalamus and cortex, maintaining arousal.
The locus coeruleus is the primary norepinephrine source, promoting wakefulness and attention.
Orexin (hypocretin) neurons in the lateral hypothalamus stabilize wakefulness and are lost in narcolepsy[2].
The ventrolateral preoptic area and median preoptic nucleus inhibit wake-promoting neurons during sleep.
The suprachiasmatic nucleus is the master circadian clock, coordinating sleep-wake cycles with light exposure.
Sleep disorders in Parkinson's:
The sleep-wake circuit connects to:
The wake-promoting system relies on multiple neurotransmitters that collectively maintain cortical arousal and alertness throughout the waking state[4]. Different populations of neurons contribute to specific aspects of wakefulness, and their coordinated activity ensures stable behavioral arousal.
Norepinephrine (Locus Coeruleus)
The locus coeruleus (LC) is the sole source of norepinephrine (NE) in the forebrain and projects to virtually all cortical and subcortical regions[4:1]. LC neurons fire most rapidly during wakefulness, reduce firing during non-REM (NREM) sleep, and cease firing during REM sleep[5]. This firing pattern corresponds to the LC's role in maintaining cortical tone and behavioral arousal. The NE released from LC terminals acts on alpha-adrenergic receptors to enhance signal-to-noise ratio in target neurons, improving information processing in sensory and cognitive cortices.
Serotonin (Dorsal Raphe)
The dorsal raphe nucleus (DRN) provides the major serotonergic input to the forebrain and is critical for mood regulation and arousal[6]. Serotonergic neurons show highest activity during wakefulness, reduced activity during NREM sleep, and minimal activity during REM sleep. The DRN interacts extensively with other wake-promoting systems, particularly the orexin and histogram systems, to coordinate arousal states.
Histamine (Tuberomammillary Nucleus)
The tuberomammillary nucleus (TMN) is the sole source of histamine in the brain and promotes wakefulness through histaminergic projections throughout the cortex[7]. Histamine release peaks during wakefulness and is minimal during sleep. Antihistaminergic medications that cross the blood-brain barrier produce drowsiness as a side effect, demonstrating the histamine system's essential role in arousal.
Basal Forebrain Cholinergic Neurons
The basal forebrain cholinergic system comprises large neurons in the medial septal nucleus, vertical diagonal band nucleus, and nucleus basalis of Meynert that project to the hippocampus and cortex[8]. These neurons fire maximally during REM sleep and waking, releasing acetylcholine to enhance cortical activation and enable REM sleep-associated cortical desynchronization. They are essential for cortical plasticity and attention.
Pontine Tegmental Cholinergic Neurons
Cholinergic neurons in the pedunculopontine tegmental nucleus (PPT) and laterodorsal tegmental nucleus (LDT) provide cholinergic input to the thalamus, promoting thalamocortical activation during both wakefulness and REM sleep[9]. These "REM-on" cells are active during REM sleep and wakdfulness but silent during NREM sleep.
Orexin/Hypocretin System
The orexin-producing neurons in the lateral hypothalamus are essential for stabilizing wakefulness[2:1]. These neurons project widely to all major wake-promoting centers and release orexin-A and orexin-B peptides that act on orexin-1 (OX1R) and orexin-2 (OX2R) receptors[@cortwright2012]. Loss of orexin neurons causes narcolepsy with cataplexy, demonstrating that the orexin system is not required for initiating wakefulness but for maintaining it throughout the day[10]. Orexin neurons are inhibited by GABAergic sleep-promoting neurons and are excited by wake-promoting neurotransmitters.
Melanin-Concentrating Hormone
Melanin-concentrating hormone (MCH) neurons are intermixed with orexin neurons in the lateral hypothalamus and promote NREM and REM sleep, particularly the theta-wave-rich REM sleep seen in narcolepsy[11].
The sleep-promoting system uses inhibitory neurotransmitters, primarily GABA and galanin, to suppress wake-promoting neurons and actively initiate and maintain sleep states[5:1].
Ventrolateral Preoptic Area
The ventrolateral preoptic area (VLPO) contains GABAergic and galaninergic neurons that selectively innervate and inhibit wake-promoting neurons[1:1]. These include projections to the locus coeruleus, dorsal raphe, tuberomammillary nucleus, and orexin neurons. VLPO neurons are maximally active during sleep, particularly NREM sleep, and their activity is regulated by circadian and homeostatic sleep drive.
Median Preoptic Nucleus
The median preoptic nucleus (MnPO) contains sleep-active GABAergic neurons that promote sleep and are reciprocally connected with the VLPO[12]. The MnPO integrates thermal and circadian signals to regulate sleep timing.
The switch between wakefulness and sleep involves coordinated inhibition between wake-on and sleep-on neuronal populations[7:1]. Falling asleep requires disfacilitation of wake-promoting neurons, while the active inhibition by VLPO neurons ensuring sleep maintenance. The switch involves reciprocal inhibition creating bistable circuit dynamics.
The suprrachiasmatic nucleus (SCN) is the master circadian clock and coordinates daily rhythms in sleep-wake cycles with light-dark cycles[13]. The SCN contains approximately 20,000 neurons that generate ~24-hour autonomous rhythms through transcription-translation feedback loops involving clock genes (BMAL1, CLOCK, PER, CRY). The SCN synchronizes the sleep-wake circuit to the external light environment.
Two-process model of sleep regulation: process S (homeostatic sleep drive) builds during wakefulness and declines during sleep, while process C (circadian alerting potential) varies ~24 hours[14]. The interaction between these processes determines optimal sleep timing.
REM sleep behavior disorder (RBD) is a parasomnia characterized by loss of muscle atonia during REM sleep, leading to complex motor behaviors during dreams[3:1]. RBD is now recognized as a prodrome to synucleinopathies including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. The pathophysiology involves degeneration of sublaterodorsal nucleus neurons that normally block muscle activity during REM sleep.
Neurodegeneration often disrupts circadian rhythms through damage to the SCN and its connections[15]. Sleep fragmentation, reduced sleep efficiency, and reversed sleep-wake patterns (sundowning) are common in Alzheimer's disease[16]. The suprachiasmatic nucleus shows decreased vasopressin expression in AD, correlating with circadian rhythm disturbances.
Sleep disturbances may serve as early biomarkers for neurodegeneration[17]:
Sleep disorders in Parkinson's disease are among the earliest and most debilitating non-motor symptoms:
Pathophysiology: Neurodegeneration in the LC, DRN, and orexin systems undermines the wake-promoting infrastructure[17:1]. Degeneration of the sublaterodorsal nucleus causes RBD. Lewy bodies in the SCN disrupt circadian rhythms.
Sleep disruption in AD reflects both neurodegenerative burden and circuit dysfunction[16:1]:
Pathophysiology: Neurofibrillary tangles in the hypothalamus disrupt sleep-wake circuits. Amyloid deposition in the basal forebrain reduces cholinergic tone. SCN dysfunction arises from tau pathology.
Understanding sleep-wake circuit dysfunction enables targeted interventions:
Sleep and immunity have bidirectional relationships: sleep deprivation impairs immunity while inflammatory cytokines promote sleep.
Memory T-cell formation: Sleep enhances formation of memory T-cells through growth hormone and prolactin release during slow-wave sleep.
Cytokine production: IL-1 and TNF are promoted during sleep and suppress wake-promoting neurons.
Neuroinflammation in neurodegeneration disrupts sleep through:
Saper, C.B. et al. The sleep switch: hypothalamic control of sleep and wakefulness. Trends in Neurosciences. 2001. ↩︎ ↩︎
de Lecea, L. et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proceedings of the National Academy of Sciences. 1998. ↩︎ ↩︎
Arnulf, I. REM sleep behavior disorder: a prodrome to neurodegeneration?. Movement Disorders. 2005. ↩︎ ↩︎
Jones, B.E. Arousal and wakefulness: multiple neurotransmitter systems in sleep-wake control. Progress in Brain Research. 2020. ↩︎ ↩︎
Saper, C.B. et al. Sleep state switching. Neuron. 2010. ↩︎ ↩︎
Cho, J.R. et al. Dorsal raphe nucleus modulates sleep and wakefulness. Neuron. 2017. ↩︎
Lu, J. et al. A neural circuit switch for sleep-to-wake transitions. Nature Reviews Neuroscience. 2006. ↩︎ ↩︎
Sherin, J.E. et al. Innervation of cholinergic basal forebrain neurons by GABAergic sleep-promoting neurons. Journal of Neuroscience. 1999. ↩︎
Fuller, P.M. et al. Neurobiology of the sleep-wake cycle. Sleep Medicine Clinics. 2011. ↩︎
Kohlmeier, K.A. et al. Orexin and sleep: molecular, anatomical and functional interactions. Current Topics in Medicinal Chemistry. 2008. ↩︎
Svare, J. et al. Orexin system and narcolepsy pathophysiology. Current Opinion in Neurobiology. 2019. ↩︎
Liu, D. et al. A sleep-wake circuit in the forebrain. Current Opinion in Neurobiology. 2017. ↩︎
Wulff, K. et al. Circadian rhythms and neurodegeneration. Nature Reviews Neurology. 2010. ↩︎
Postnova, S. et al. Mathematical modeling of sleep-wake dynamics. Journal of Sleep Research. 2019. ↩︎
Bokeny, D. et al. Circadian disruption and neurodegenerative disease. Journal of Molecular Medicine. 2019. ↩︎
Pace-Schott, E.F. et al. Sleep and circadian rhythms in Alzheimer disease. Nature Reviews Neurology. 2012. ↩︎ ↩︎
Andersen, M.L. et al. Sleep disorder in neurodegenerative diseases. Nature and Science of Sleep. 2020. ↩︎ ↩︎